Skip to main content
Premium Trial:

Request an Annual Quote

Marina Completes Enrollment of First Cohort in FAP Drug Trial

Premium

Marina Biotech said this week that it has completed enrollment of the first cohort in a phase I study of its RNAi-based treatment for its familial adenomatous polyposis treatment CEQ508.

The drug uses orally delivered attenuated Escherichia coli to transcribe shRNAs targeting beta-catenin, an oncogene that plays a role in the development of colorectal polyps that characterize the disease. The company began the clinical trial last month (GSN 3/17/2011).

"We're into our second week of drug administration with our first patient and anticipate dosing the subsequent two patients in this group in the coming weeks,” Daniel Chung, a clinician at Massachusetts General Hospital and the phase I trial's principal investigator, said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.